Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Pioneer launches new regional programmes to accelerate early-stage innovations

Pioneer Group has announced the launch of new regional accelerator programmes designed to support early-stage life science and tech companies accelerate their journey to market.

Pioneer delivers the most comprehensive suite of accelerator and venture building activity across the UK and Ireland, helping founders to transfer cutting-edge discovery into visionary ventures that scale. To date, Pioneer has supported more than 350 entrepreneurs and funded over 195 companies, which have collectively raised £830 million in investment.

Principal Regulatory Affairs Consultant (CMC Small Molecules)

Scendea is seeking a highly motivated individual to join our global team as a full-time Principal Consultant (CMC, small molecules experience). The ideal candidate will have a proven track record in CMC for small molecule drug development, with expertise in process development, scale-up, regulatory submissions, and the pre-approval life cycle management of small molecule products. This is a hybrid position, affiliated to either of our UK or Australia offices, with a requirement to work in the office a minimum of one day per month.

Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma

Cambridge, UK –  22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination of a class I selective HDAC inhibitor and an mTOR inhibitor, in adolescents and adults with relapsed, refractory sarcoma, with a focus on osteosarcoma.

Business Support Administrator

Scendea is seeking a Business Support Administrator to join our UK team in a 12-month fixed-term position. The role is full-time, Monday to Friday during standard office hours, and will be based at our Bishop’s Stortford office, with an anticipated start date of September 2026. This position reports into the Business Support Manager.

The successful candidate will be a highly organised professional with experience in systems administration, strong multitasking abilities, and excellent attention to detail.

The Company

Now On Demand: From Preclinical to First-in-human Live Q&A

We recently hosted our Ask the Experts Live Q&A: From Preclinical to First-in-Human.

In this session, our experts explored the strategic decisions that shape early clinical success, covering key considerations for transitioning from preclinical development into first-in-human studies. Drawing on their extensive experience, they discussed common challenges, practical approaches to reducing development risk, and the critical decisions that can help keep programmes on track.

Associate Principal Scientist – Peptide Development Chemistry - Pharmaceutical Sciences (PS)

About AstraZeneca

AstraZeneca is a global, science-led, patient-focused biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines for some of the world’s most serious diseases. But we’re more than one of the world’s leading pharmaceutical companies. At AstraZeneca, we are pioneering new frontiers by identifying and treating patients earlier, working towards the aim of eliminating cancer as a cause of death.

Senior / Principal Scientist - RNA Engineering for Cell and Gene Therapy

Plurify is an early-stage, fast-moving biotech building platform technologies to help unlock the next generation of stem cell and gene therapies. Our work targets the most stubborn manufacturing bottlenecks - including the unwanted residual cells and plasmids left behind during cell and gene therapy production - with scalable, precisely targeted solutions. With several Innovate UK grants and strong private backing behind us, we're growing the team.

💡 THE OPPORTUNITY

Subscribe to